Donald School Journal of Ultrasound in Obstetrics and Gynecology

Register      Login

VOLUME 1 , ISSUE 2 ( April-June, 2007 ) > List of Articles


Vascular Ultrasound in Gynecology

Atsushi Yoshida, Tsutomu Tabata, Toshiharu Okugawa, Takashi Sugiyama, Norimasa Sagawa

Keywords : Vascular ultrasound,carotid artery,radial artery,flow-mediated vasodilation,deep vein thrombosis

Citation Information : Yoshida A, Tabata T, Okugawa T, Sugiyama T, Sagawa N. Vascular Ultrasound in Gynecology. Donald School J Ultrasound Obstet Gynecol 2007; 1 (2):10-15.

DOI: 10.5005/jp-journals-10009-1093

License: CC BY-NC 4.0

Published Online: 01-03-2008

Copyright Statement:  Copyright © 2007; The Author(s).


The usefulness of the vascular ultrasound in the filed of gynecology is now well recognized. The intima-media thickness (IMT) and the elastic property of the common carotid artery are reported to be associated with the risk of cardiovascular diseases and are thought to be influenced by menopause. The assessment of the flow-mediated vasodilation (FMD) of the brachial artery is a noninvasive method for the evaluation of vascular endothelial function and is reported to be associated with menopause or hormone replacement therapy. Certain gynecological situations such as contraceptive use or hormone replacement therapy are reported to increase the risk of thrombosis. For the screening of deep vein thrombosis of the lower extremities in the gynecological diseases, compression ultrasonography (CUS) is useful.

PDF Share
  1. Evaluation of a scoring system for extracranial carotid atherosclerosis. Stroke: 1986;17:270-5.
  2. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.
  3. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Atheroscler Thromb 1991;11:1245-9.
  4. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery heart disease. Eur Hear J 1994;15:781-5.
  5. Determinants of femoral and carotid artery atherosclerosis. J Intern Med 1994;236;79-84.
  6. Radial artery hypertrophy occurs in coronary atherosclerosis and is independent of blood pressure. Clin Sci 2001;100:509-16.
  7. A dietary and exercise intervention slows menopause-associated progression of subclinical atherosclerosis as measured by intima-media thickness of the carotid arteries. J Am Coll Cardiol 2004;44:579-85.
  8. The effect of hormone replacement therapy on carotid arteries: measurement with a high frequency ultrasound system. Maturitas 1998;30:63-8.
  9. Hormon replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis 2003;166:163-70.
  10. No association of menopause and hormone replacement therapy with carotid artery intima-media thickness. Circulation. 1996;94:1857-63.
  11. Carotid wall thickness and years since bilateral oophorectomy: the Los Angeles Atherosiclerosis Study. Am J Epidemiol 2002;156:438-44.
  12. Assessment of the intima-media thickness of radial artery using ultrasonography-Effects of aging and menopause. Jpn J Med Imaging, 2000;19,29-36.
  13. Menopausal status and distensibility of the common carotid artery. Arterioscler Thromb Vasc Biol 1999;19:713-7.
  14. The effect of hormone replacement therapy on arterial distensibility and compliance in perimenopausal women: a 2-year randomised trial. Atherosclerosis 2000;152:149-57.
  15. Hormon replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. J Am Coll Cardiol 2000;36:1789-96.
  16. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
  17. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471-6.
  18. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 1998;15:215-8.
  19. Effects of oral L-arginine on endothelium- dependent vasodilation and markers of inflammation in healthy postmenopausal women. J Am Coll Cardiol 2000;35:271-6.
  20. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf) 1996;45:435-41.
  21. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
  22. Progesterone does not influence vascular function in postmenopausal women. J Hypertens 2003;21:1145-9.
  23. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993;88:2163-71.
  24. Is hormone replacement therapy cardioprotective? Decision-making after the heart and estrogen/ progestin replacement study. Can J Cardiol 2000;16 Suppl A:14A-19A.
  25. Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials. Cardiology 2005;104:143-47.
  26. HRT as secondary prevention of cardiovascular disease. Maturitas 2004;47:315-8.
  27. Modulation of endothelium-dependent flow-mediated vasodilation of the brachial artery by sex and menstrual cycle. Circulation 1995;92;3431-5.
  28. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088-95.
  29. Pulmonary Embolism. Lancet 1961;2:1146-7.
  30. Deep vein thrombosis. Lancet 2005;65:1163-74.
  31. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
  32. Risk factors for fatal venous thromboembolism in young women: a case- control study. Int J Epidemiol 1992;21:48-52.
  33. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ 2001;21:131-4.
  34. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
  35. Estrogen, progestogens and thrombosis. J Thromb Haemost 2003;1;1371-80.
  36. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
  37. Prevalence, causes, and impact of cancer-associated thrombosis. Am J Health Syst Pharm 2005;62:S4-6.
  38. Venous thromboembolism and cancer. Lancet 1998;351:1077-80.
  39. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165:1782-7.
  40. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 2005;99:119-25.
  41. Diagnosis of venous thromboembolic disease in cancer patients. Oncology 2003;17:126-35.
  42. Venous sonography for the diagnosis of asymptomatic deep vein thrombosis in patients with cancer undergoing chemotherapy. J Ultrasound Med 2004;23:655-8.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.